Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

49.33
+1.092.26%
Volume:365.42K
Turnover:18.04M
Market Cap:2.37B
PE:-16.16
High:50.34
Open:48.16
Low:47.44
Close:48.24
52wk High:50.34
52wk Low:14.11
Shares:47.98M
Float Shares:30.39M
Volume Ratio:1.64
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0525
EPS(LYR):-2.8633
ROE:-39.96%
ROA:-25.78%
PB:5.60
PE(LYR):-17.23

Loading ...

Rapport Therapeutics to Host Virtual KOL Event on Bipolar Mania and RAP-219 Program

Reuters
·
Yesterday

Rapport Therapeutics Chief Development Officer Krishnaswamy Yeleswaram Disposes of 404 Common Shares Worth $20,159.6

Reuters
·
Aug 21

Analysts Have Conflicting Sentiments on These NA Companies: ServiceTitan, Inc. Class A (TTAN), Rapport Therapeutics, Inc. (RAPP) and Amentum Holdings, Inc. (AMTM)

TIPRANKS
·
Aug 20

Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and SpaceX (SPCX)

TIPRANKS
·
Aug 20

Does Widening Losses And Higher EPS Drag Change The Bull Case For Rapport Therapeutics (RAPP)?

Simply Wall St.
·
Aug 20

Rapport Therapeutics Price Target Maintained with a $65.00/Share by BTIG

Dow Jones
·
Aug 19

Rapport Therapeutics price target raised to $75 from $68 at Raymond James

TIPRANKS
·
Aug 17

Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Stifel Nicolaus

TIPRANKS
·
Aug 13

Rapport Therapeutics CEO Abraham Ceesay Sells 51,499 Shares Worth $2.41 Million

Reuters
·
Aug 13

Rapport Therapeutics Price Target Raised to $66.00/Share from $40.00 by HC Wainwright & Co.

Dow Jones
·
Aug 13

Douglas Tsao Boosts Rapport Therapeutics Price Target to $66 on Strong RAP-219 Differentiation and Robust Phase 2 Data

TIPRANKS
·
Aug 13

Analysts Offer Insights on NA Companies: Rapport Therapeutics, Inc. (RAPP) and Honeywell Aerospace (HONA)

TIPRANKS
·
Aug 06

Truist Financial Keeps Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Aug 06

Rapport Therapeutics Price Target Maintained with a $65.00/Share by BTIG

Dow Jones
·
Aug 06

Rapport Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Rapport Therapeutics Q2 EPS $(1.19) Misses $(0.96) Estimate

Benzinga Earnings
·
Aug 05

Rapport Therapeutics Q2 FY26 Net Loss Widens to $56.6 Million; R&D Expense More than Doubled to $51.4 Million

Reuters
·
Aug 05

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

THOMSON REUTERS
·
Aug 05

Rapport Therapeutics CEO Abraham Ceesay Sells 2,210 Shares Worth $92,999.37

Reuters
·
Jul 30

William Blair Initiates Rapport Therapeutics at Outperform

MT Newswires Live
·
Jul 28